Primary Care/Hospitalist
RSSArticles
-
Menopausal Hormonal Therapy and Breast Cancer Risk: Are Old Data Relevant to Today’s Practice?
An individual-participant meta-analysis of prospective studies revealed menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.
-
Taming of the Flu: What’s New for 2020
The 2019-2020 flu season is already among us, and it is imperative that those healthcare practitioners on the frontline have current knowledge of prevention and treatment strategies. Both influenza A and B strains have been identified, and their predominance varies by region and age group.
-
Researchers Examine Use of Dichloroacetate in Endometriosis Treatment
The authors of a new scientific paper indicate that dichloroacetate, investigated as a potential cancer treatment, may be effective against endometriosis. Finding a new treatment option would augment current treatment strategies of hormone therapy and surgery, which involve significant side effects and recurrence after treatment.
-
Research Focuses on Medroxyprogesterone Acetate in Cervical Cancer Prevention
Preliminary research suggests that medroxyprogesterone acetate, the active ingredient in the contraceptive injection DMPA, may be effective in preventing cervical cancer.
-
Policy Update Advocates Teen Access to Emergency Contraception
To help prevent unplanned pregnancy among adolescents, the American Academy of Pediatrics has issued an updated policy statement on emergency contraception (EC) to educate providers on use of EC in adolescents, and advocate for expanded access for teens.
-
Investigational Contraceptive Patch Clears FDA Panel Vote
Twirla, an investigational combined hormonal contraceptive patch, is under review by the FDA. In an October 2019 meeting, the patch received a 14 to 1 vote from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee.
-
FDA Approves Liletta IUD for Six Years of Effective Use
The FDA has approved the Liletta levonorgestrel intrauterine device (IUD) for six years of effective use. The 52 mg device, similar in size to the Mirena IUD, was approved for the U.S. in February 2015.
-
The Time for Contraceptive Revolution Is Now
While the 20th century yielded new contraceptives in the form of pills, rings, patches, intrauterine devices, and implants, it is time for new exploration into further birth control options.
-
Can You Interpret This Rhythm?
The long lead II rhythm strip in the figure was obtained from a middle-aged woman with syncope and hypotension. What can you say about the rhythm?
-
Minocycline Topical Foam (Amzeeq)
Minocycline topical foam is indicated to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients ≥ 9 years of age.